Tickerover
Healthcare

ASTH Stock Analysis

Astrana Health, Inc. · current price $37.94 (-1.11% today)

Top-tier setup — 48% revenue growth, 4/4 EPS beats. Momentum, fundamentals and macro indicators are aligned.
★★★★★
Top Tier
📊

The six-pillar scorecard

Momentum
55
Drifting higher
price trend
Growth
27
Barely growing
sales & profit growth
Quality
40
Some weak spots
profitability & balance sheet
Valuation
75
Looks cheap
is the price fair?
Sentiment
51
Positive mood
analyst & crowd mood
Risk
53
Moderate risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
GrowthGrowth: 95951-month momentum1-month momentum: 6262RSI zoneRSI zone: 7070Earnings qualityEarnings quality: 8989Near 52w highNear 52w high: 8888Analyst consensusAnalyst consensus: 7070News sentimentNews sentiment: 9595
Margin profileWhat survives each step down the income statement.
GrossGross: 10.5%10.5%OperatingOperating: 3.5%3.5%NetNet: 1.1%1.1%Free cash flowFree cash flow: 4.0%4.0%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +9.6% vs estimate+10%2026-062026-03: +13.8% vs estimate+14%2026-032025-12: +28.6% vs estimate+29%2025-122025-09: +10.7% vs estimate+11%2025-09
👁

Hype Check

Reading ASTH’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading ASTH’s filings…

📣

Latest earnings

LAST EARNINGS Astrana Health, Inc. (ASTH)

Latest earnings

EPS
$0.67 vs $0.61 est · +10.7% vs estimate BEAT
Stock reaction (1M)
+3.5%
Beat streak
4 of last 4 quarters
💰

Valuation

P/E
46.3×
Forward P/E
10.7×
Price / Sales
0.5×
Price / Book
2.3×
EV / EBITDA
13.1×
Analyst target
$51.50
Target range
$41.00 – $65.00
Implied upside
+35.8%
🩺

Financial health

Gross margin
10.5%
Operating margin
3.5%
Net margin
1.1%
FCF margin
4.0%
Return on equity
6.9%
Debt / equity
1.64
Revenue growth YoY
+48.5%
EPS growth YoY
+110.5%
📈

Technicals

$18.0852-week range$51.60
RSI (14)
47
50-day MA
$41.14
200-day MA
$30.97
ATR (14)
1.95
Beta
0.90
1-month return
+3.5%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$0.67$0.61+10.7%Beat
2025-12-31$0.42$0.33+28.6%Beat
2026-03-31$0.74$0.65+13.8%Beat
2026-06-30$0.80$0.73+9.6%Beat
Beat 4 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.12%
Beta
0.90
📰

Latest news on ASTH

🔗

Similar stocks in Healthcare

Frequently asked

What is ASTH's Quant Score?

Astrana Health, Inc. (ASTH) currently has a TickerMover Quant Score of 69/100, rated ★★★★★ Top Tier. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Astrana Health, Inc. (ASTH) a buy?

TickerMover does not give buy or sell recommendations. ASTH scores 69/100 (★★★★★ Top Tier) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is ASTH's score updated?

ASTH's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for ASTH →